Navigation Links
Dr. Neil Sadick Presents on Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology
Date:2/6/2008

NAPA, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that Dr. Neil Sadick presented on Pyratine-6(TM) at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio, Texas.

In his presentation to the Academy, Dr. Sadick, a prominent New York dermatologist, outlined the therapeutic benefits of Senetek's Pyratine-6(TM) for the treatment of aging skin. Dr. Sadick reviewed clinical data demonstrating the ability of Pyratine-6(TM) to ameliorate the visible signs of skin aging and significantly reduce erythema -- redness of the skin caused by capillary congestion.

In independent clinical trials at the University of California, Irvine and RCTS, an independent laboratory in Irving, Texas, Pyratine-6(TM) demonstrated significant efficacy in the treatment of fine wrinkles, skin roughness, acne lesions, overall skin aging, and significantly reduced erythema as early as two weeks from onset of use. Pyratine-6(TM) was also shown to increase skin moisture content and was well tolerated by all subjects producing no measurable skin irritation or signs of allergic contact dermatitis with twice-daily application over the 12-week study periods.

Frank Massino, Chairman and Chief Executive Officer of Senetek stated, "We are very pleased by the recognition Pyratine-6(TM) has received at this important dermatological symposium."

About Senetek PLC

Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.

For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward- looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2006. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bush Budget Represents Double Whammy Hit on U.S. Seniors Medicare-Financed Nursing Facility Care
2. Womans Day Presents the 5th Annual Red Dress Awards Honoring Women Who Are Leaders in the Fight Against Heart Disease
3. Center for Science Writings presents: Big Fat Lies: The Truth about Diet, Exercise and Obesity
4. IQWiG presents a concept for cost-benefit assessment methods in the German health care system
5. Illness Presents Diabetics With Special Challenges
6. A New Book on Sexual Medicine Calls Attention to The Couple and Presents State-of-the Art Treatments for Sexual Dysfunction
7. GlaxoSmithKline Presents Innovative Neuroscience Pipeline
8. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
9. New book presents comprehensive survey of research into the molecular basis of aging
10. NHCAA Presents 2007 Fraud Investigation of the Year Award to U.S. Departments of Justice, HHS, and Treasury for Convicting Internet Pharmacy Drug Kingpin
11. National Partners from St. Jude Halloween Promotion Presents More Than $1.7 Million to Help Fight Childhood Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , ... February 20, 2017 , ... ... offering a full range of emergency dental care at his office, Antoine Dental ... When patients experience dental emergencies, they are at risk for serious complications and ...
(Date:2/20/2017)... FL (PRWEB) , ... February 20, 2017 , ... ... gift from Constellation Brands to purchase a new ultrasound-enhanced thrombolysis machine, a state-of-the-art ... waves. The gift was facilitated by the Pepin Family Foundation. , “We greatly ...
(Date:2/19/2017)... ... February 19, 2017 , ... "At your fingertips" electronic access ... and the Delaware Health Information Network (DHIN) have partnered to improve connectivity of ... health information exchange, DHIN stores and shares real-time health data for more than ...
(Date:2/18/2017)... ... February 17, 2017 , ... Butler Mobility invited Ken Matthews to visit ... Butler products. Ken was impressed with the safety and reliability of the Stannah ... on his show. This endorsement by Ken Matthews can be heard on News ...
(Date:2/18/2017)... MANDEVILLE, La. (PRWEB) , ... February 18, 2017 ... ... Network released today provides the latest information and contact points to easily connect ... including home care, assisted living, and elder-care funding. It also conveys material on ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, ... technologies market is expected to grow at a CAGR of 9.4% ... expected to grow at a CAGR of 9.5% from 2017 to ... in 2026. ... this report will benefit you Read on to discover how ...
(Date:2/17/2017)... Feb. 17, 2017 Theravance Biopharma, Inc. ... the "Company") today announced the presentation of positive ... orally administered pan-Janus kinase (JAK) inhibitor designed to ... Congress of the European Crohn,s and Colitis Organization ... further data from its completed Phase 1 study ...
(Date:2/17/2017)... 2017   Risperdal lawsuits involving gynecomastia (male breast ... use of the atypical antipsychotic medication continue to move ... of Common Pleas, where the state,s Risperdal docket has ... a notice posted on the Court,s website , ... March 9, 2017 at 11:00 a.m. (In Re: Risperdal ...
Breaking Medicine Technology: